Phase 4 HIV and AIDS Trial, Recruiting NCT03132311 Sponsor: Oswaldo Cruz Foundation Condition: HIV and AIDS
Back to Hiv Aids

Phase 4 HIV and AIDS Trial, Recruiting

NCT03132311
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to under 60 years old who are living with HIV
  • People living with HIV whose recent blood test (within the last 6 months) shows an immune cell count (CD4) above 200 — or, if no recent test is available, those with an undetectable HIV level in the blood and a previous CD4 count above 350
  • Adults aged 18 to under 60 years old who do not have HIV and are in general good health
  • People who have never received a Yellow Fever vaccine
  • People who are willing to take part and sign a consent form

Who may not be able to join:

  • People with certain serious ongoing health conditions, including poorly controlled diabetes, kidney failure requiring dialysis, liver failure or cirrhosis, or most types of cancer (non-melanoma skin cancer and certain HIV-related cancers may be exceptions — confirm with trial site)
  • People who have been taking strong immune-suppressing medications (such as prednisone at 20mg per day or more, for 7 or more days in the month before joining)
  • Women who are pregnant
  • People with an allergy or sensitivity to eggs or chicken protein, an allergy to the antibiotics erythromycin or kanamycin, or a condition called hereditary fructose intolerance
  • People who have received immunoglobulins, blood products, or a live attenuated (weakened live virus) vaccine within certain timeframes before joining (3 months for blood products; 1 month for live vaccines)
  • People with a history of thymus gland problems, including removal of the thymus (thymectomy) or a tumour of the thymus (thymoma)
  • People currently using a type of HIV medication known as anti-CCR5 drugs
  • People who have signs of a serious acute illness or a fever (underarm temperature of 38°C or above) at the time of joining
  • HIV-negative participants who return a positive HIV rapid test result

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +552122707064

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Oswaldo Cruz Foundation
Registry
ClinicalTrials.gov
Start date
29 May 2017
Est. completion
1 December 2018

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Immunogenicity; Immunogenicity; Immunogenicity; Immunogenicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov